Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 5,064 shares at $130.28 ($666K) on 2018-03-13, disclosed to the SEC on 2018-03-15.
Open-market sale of $666k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $128.85 | 100 | $13K | 1.9% |
| 2 | $130.28 | 500 | $65K | 9.8% |
| 3 | $131.41 | 400 | $53K | 7.9% |
| 4 | $132.48 | 441 | $58K | 8.8% |
| 5 | $132.48 | 441 | $58K | 8.8% |
| 6 | $134.05 | 100 |
| $13K |
| 2.0% |
| 7 | $131.05 | 895 | $117K | 17.6% |
| 8 | $131.05 | 895 | $117K | 17.6% |
| 9 | $132.02 | 646 | $85K | 12.8% |
| 10 | $132.02 | 646 | $85K | 12.8% |
| Total | $131.51 avg | 5,064 | $666K | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |